Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD

Slides:

Advertisements

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Advertisements

CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non–Small-Cell Lung Cancer in a Prospective Trial: CALGB Martin J. Edelman, MD, Lydia.

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Figure 5 Dendritic cells in liver inflammation

Oncology Meets Immunology: The Cancer-Immunity Cycle

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig

ALK FISH and IHC: You Cannot Have One without the Other

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor Rajeev Dhupar, MD, Lauren Van Der Kraak, PhD, Arjun Pennathur, MD, Matthew.

Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC

Electronic Updates for JTO Readers

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer

Targets for immunotherapy of liver cancer

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

Robert J Korst, MD, Ronald G Crystal, MD

Alterations of the Immune System in Thymic Malignancies

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer Justin F. Gainor, MD, Sai-Hong Ignatius Ou, MD, PhD, Jennifer.

LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis

Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non–Small-Cell Lung.

Nat. Rev. Endocrinol. doi: /nrendo

Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer Antonio Calles, MD, Xiaoyun Liao, MD,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Thomas S. Griffith, Thomas A. Ferguson Immunity

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Volume 33, Issue 4, Pages (October 2010)

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

“The Best-Laid Plans … Often go Awry …”

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Immunotherapy for Lung Cancer

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Adam Falconi, BSc, Pharm, Gilberto Lopes, MD, MBA, Jayson L

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies Samuel T Workenhe, Karen L Mossman

Mitotic Inhibitors Journal of Thoracic Oncology

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Phase I Study of Lenalidomide in Solid Tumors

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies Samuel T Workenhe, Karen L Mossman

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Vaccines for Lung Cancer

IASLC 6th Latin American Conference on Lung Cancer

Aritoshi Hattori, MD, Kenji Suzuki, MD

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Cytokine Gene Therapy for Malignant Pleural Mesothelioma

A B3 Type-Thymoma in a 7-Year-Old Child with Myasthenia Gravis

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.

Biomarkers in Early-Stage Non–Small-Cell Lung Cancer: Current Concepts and Future Directions Mauricio Burotto, MD, Anish Thomas, MD, Deepa Subramaniam,

Presentation transcript:

Clinical Trials Integrating Immunotherapy and Radiation for Non–Small-Cell Lung Cancer Megan E. Daly, MD, Arta M. Monjazeb, MD, PhD, Karen Kelly, MD Journal of Thoracic Oncology Volume 10, Issue 12, Pages 1685-1693 (December 2015) DOI: 10.1097/JTO.0000000000000686 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Radiotherapy induces multiple immunomodulatory changes that can potentially influence the effectiveness of immunotherapy. Shown above from left to right and in Table 1: radiation may lead to direct tumor cell killing; upregulation of immunogenic cell surface markers, such as mhc-1; secretion of danger signals and cytokines, such as TNF-alpha; induction of immunogenic cell death via calreticulin and HMGB-1, among others; improved homing of immune cells, such as cytotoxic T lymphocytes to tumor; improved antigen presentation by mechanism including priming of dendritic cells; a shift in TAM from the M2 to M1 phenotype; and upregulation of cell surface PD-L1, among others. MHC-1, major histocompatibility complex 1; HMGB-1, high mobility group protein B1; TAM, tumor-associated macrophage; PD-L1, programmed cell death ligand-1. Journal of Thoracic Oncology 2015 10, 1685-1693DOI: (10.1097/JTO.0000000000000686) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions